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Abstract Healthcare reforms aim to change certain parts
of the health system to improve quality of care, access, or
financial sustainability. Traditionally, healthcare reform is
understood as an action undertaken by a government at a
national or local level. However, bottom-up changes can
also lead to improvements in the health system. This paper
describes the efforts of a coordinated multi-stakeholder
advocacy group in Spain to promote a more cost-effective
and patient-centred treatment for people receiving renal
replacement therapy and assesses the outcomes of their
advocacy for health system financing and patient satisfac-
tion. It concludes that bottom-up initiatives do indeed have
the power to change health policy and that policy makers
should pay attention to their arguments.
Key Points for Decision Makers
A multi-stakeholder group (GADDPE) was set up to
initiate and sustain coordinated efforts targeting both
policy makers and individual patients and providers
to act upon the barriers that led to an unfavourable
situation for home-based peritoneal dialysis (PD).
After 5 years, the use of PD has increased
significantly throughout the country, as has patients’
satisfaction with the information they receive,
leading to potentially important savings to the
Spanish social and healthcare system.
Raising awareness and gathering the right
stakeholders to engage decision makers can be a
viable option to initiate profound changes in
healthcare provision.
1 Introduction
The burden of chronic diseases, exacerbated by the ageing
of European populations and the impact of unhealthy
lifestyles, has become a huge threat to the sustainability of
European health systems. Spain is no exception, and while
many valuable efforts are being undertaken by Spanish
regional governments to reduce the impact of chronic
diseases on their healthcare systems [1–3], structural fac-
tors have made progress rather slow in some treatment
areas. One such area is renal-replacement therapy (RRT),
which is the most expensive of all chronic disease treat-
ments [4]. Despite strong evidence of the benefits of peri-
toneal dialysis (PD) for patients and the healthcare system,
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uptake of this treatment in Spain had been rather low over
the previous 30 years [4]. However, the efforts of a coor-
dinated multi-stakeholder group called GADDPE (acronym
for Spanish Support Group for Peritoneal Dialysis Devel-
opment) have been successful in recent years. We present
the factors that contributed to reversing a situation that
seemed set in stone only a few years ago and that can serve
as a model in other treatment areas or for other countries.
2 A Strong Imbalance in Treatments Offered
to Renal Patients
While renal transplantation is the treatment of choice in
Spain because of its cost-effectiveness and lower mortality
compared with alternative RRTs, clinical circumstances
mean only a small proportion of patients are eligible [5].
Therefore, alternative therapies are offered, and
haemodialysis (HD) has been by far the most widely used
RRT in Spain in recent decades [4]. Indeed, unlike PD, HD
is available to all patients [6], which has led to unequal
access to different RRT therapies across the country.
The prevalence of patients receiving RRT has been
growing steadily in Spain, at a rate of 17% between 2001
and 2009. As of 2011, there were 50,871 renal patients [7]
(0.1% of the population) who consumed 2.5% of the
Spanish healthcare budget [5] and 4% of the specialized
care budget [6]. In 2012, there were 51,570 RRT patients
[7] at a cost of €29,061 per patient per year [8]. A cost
analysis carried out in 2010 [9] found that HD accounted
for 73–77%, transplantation 17–21%, and PD 6% of the
aggregate costs of the Spanish RRT program.
Most (90%) of patients receiving RRT start with HD,
and half of these start with emergency treatment [10],
usually requiring hospitalization, which incurs additional
costs. For 90% of patients who start with HD, this tech-
nique becomes their chronic treatment [8].
However, evidence shows that home-based PD is asso-
ciated with improved quality of life, including amongst
older people [11, 12]. HD is 44% more costly than PD,
even without accounting for the costs of hospitalization [4].
A 2010 study [13] estimated that increasing the use of
PD to treat 30% of patients over 15 years would lead to
savings of €500 million and increase survival rates. A
report from 2013 [8] further estimated that if 30% of
patients receiving dialysis used PD, as in some EU coun-
tries, the savings in indirect costs (loss of productivity)
related to morbidity would exceed €13.5 million in Spain.
Maintaining this percentage until 2020 would save an
estimated €21 million because PD allows patients to con-
tinue working (50 vs. 22% for HD) [4] and maintain an
active lifestyle, which is important because 50% of the
patients starting dialysis in Spain are of working age [8].
Finally, a cost-effectiveness analysis of the Spanish RRT
program also showed that it would be most cost efficient to
increase the number of incident patients using PD [14].
Despite evidence showing the benefits of PD, which can
be carried out at home or at work—in contrast to HD,
which usually takes place in specialized health centres—
patients in Spain have not been routinely offered this
option.
3 A Bottom-Up Effort to Change the Situation
The provision of PD in Spain was much lower than in some
other European countries and varied greatly across Spanish
regions, so the GADDPE working group was created in
2009 as a bottom-up attempt to remedy this imbalance. Its
aim has been to promote understanding of PD in Spain by
gathering a number of stakeholders together, including
healthcare professionals, patient associations, and the
dialysis industry. Their efforts provided a comprehensive
picture of, and barriers to, the use of PD in Spain, and their
actions have led to significant improvements in the provi-
sion of PD in the course of a few years.
In its 2010 White Paper, GADDPE highlighted that not
all patients were able to access PD because of a lack of
programs and deployment [6]. In addition, there were
tremendous disparities between regions and even within
certain districts. The use of PD was generally higher in
areas that promoted renal transplantation. The use of home-
based PD ranged from 4 to 30% of dialysis patients across
Spanish regions [4].
However, since the White Paper was published and
GADDPE began their concerted efforts, the number of
incident dialysis patients selecting PD has undergone a
relative increase of 33.5% from 12.7 to 16.9% over
6 years, reaching 20% in some regions (e.g., Asturias
and the Basque Country) [15]. The figures for prevalent
PD patients have consequently increased in relative
number by 20.5% from 9.6 to 11.6%. Although there is
still room for improvement, this shows that, despite a
seemingly irreversible situation, the actions of a bottom-
up initiative succeeded in helping transform care provi-
sion and had a positive impact for both patients and the
healthcare system.
4 Structural Barriers
GADDPE collected data, analysed various surveys of key
stakeholders, and was able to identify a series of factors
that appeared to be hindering the uptake of PD in Spain.
The group then developed recommendations for various
actors to tackle these factors [6].
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The oversupply of HD facilities across the Spanish
regions was well-established, and new hospitals were built
with oversized HD capacities, which meant hospitals were
able to offer HD to all patients. Thus, the incentive for
change was small and choice of therapy was based on non-
medical criteria related to care provision. This meant that
previous attempts to incentivize the use of PD had failed
[4, 6].
Another factor was the high percentage of patients with
an unplanned RRT start. Despite evidence showing that
non-programmed dialysis incurs worse health results as
well as higher costs [16], a large number of patients in
Spain were starting dialysis as an emergency [10]. When
patients and clinicians can plan for RRT, more patients opt
for PD (one in three vs. one in 20 for unplanned start
patients) [6]. Conversely, PD is rarely selected as treatment
for unplanned RRT. Starting RRT with emergency HD also
seems to determine whether the patient continues with that
technique, either by patient choice or because it is assumed
the patient does not require any information to make a
decision [8].
Additional hurdles identified by GADDPE included a
lack of training for nurses and specialists and lack of
appropriate knowledge about PD indications and con-
traindications. The formal training for nephrologists during
their specialization only includes 2 months on PD but
7 months on HD [6]. On another level, nursing resources
assigned to home-based PD are insufficient, particularly
compared with those for HD [4]. The low awareness from
healthcare authorities of all these issues has also influenced
the uptake of PD in Spain.
The healthcare structure therefore largely contributed to
making HD a treatment of choice for most providers, rel-
egating PD to second choice used only when HD centres
were at capacity. A national survey of hospital managers
undertaken in 2009 by ALCER, the Spanish Renal Foun-
dation, indicated they were aware of the benefits of PD but
perceived organizational issues and a lack of support from
specialists, trust in techniques, and skills to be barriers to
its use. Nevertheless, nearly half of the respondents were in
favour of implementing incentives for PD use, and an
overwhelming majority thought the use of home-based PD
would increase in coming years [6].
5 Gaps in Patient Information
and Implementation of Informed Consent
The Spanish law on the autonomy of the patient dates back
to 2002 and aims to guarantee informed consent to allow
patients to fully take part in decision-making processes
affecting their treatment [17]. Despite this, significant gaps
were identified in its application in the area of RRT. In fact,
as of 2011 only four of the 17 Spanish regions had models
of informed consent for RRT [4].
Both patients and patient associations reported a lack of
information to enable informed decisions on RRT and
insufficient knowledge about PD [10]. As a result, HD is
often chosen because knowledge about PD as an alternative
is lacking. According to a national patient survey from
2009, most patients with chronic kidney diseases (CKDs)
did not have sufficient knowledge of PD, and older people
had even poorer knowledge of the therapy [18]. Although
the law states that patient consent should be collected in
writing, this seldom happens, and informed consent reports
are often too difficult for patients to understand and com-
pleted incorrectly. Specialists who provide such informa-
tion often lack the time to inform patients properly.
6 GADDPE’s Strategic Action and Achievements
Given the structural barriers described earlier and the gaps
in patient information and informed consent, GADDPE
focused their efforts on the following four strategic areas
and achieved significant results [19]:
• Promoting decision making and informed treatment
choice among patients
• Increasing awareness in healthcare authorities of the
benefits of PD and encouraging policy initiatives to
ensure equity in patient access to RRT modalities,
leading to long-term sustainability of RRT
• Improving knowledge of PD among healthcare
professionals
• Expanding communication channels to reach the gen-
eral population and raise awareness about the value and
benefits of PD.
6.1 Promoting Decision Making and Informed
Treatment Choice Among Patients
To foster informed shared decision making among patients,
educational processes were put in place for informed RRT
choice with patient decision aids (PDAs) in most CKD
units. According to The Ottawa Decision Support Frame-
work, PDAs are tools that help people become involved in
decision making by making explicit the decision that needs
to be made, providing information about the options and
outcomes, and by clarifying personal values; they are
designed to complement rather than replace counselling
from a health practitioner.
In Spain, the previously mentioned law 41/2002 regu-
lates and allows for basic patient autonomy and rights and
obligations with regard to clinical information and docu-
mentation (BOE 274, 15 November 2002). This law covers
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the rights of patients to receive information on and choose
among therapeutic alternatives. However, given that a
culture of shared decision making and guidelines on how to
inform and educate patients on treatment choice were
lacking, GADDPE made an effort to educate on the need to
involve patients in RRT decision making as well as cre-
ating favourable opinions on this desired culture amongst
healthcare professionals.
A group of clinicians, nurses, and representatives of
ALCER (the major patient association in Spain) collaborated
to develop PDAs and a formal structured education process
that was then tested in real-life environments and progres-
sively implemented in an increasing number of nephrology
units. Patients’ choices and the final RRTmodality used were
recorded during implementation of this process in 26 Spanish
hospitals. Analysis of this registry showed a 50:50 split
between patients choosing PD or HD plus an increase in pre-
emptive transplantation choice. The use of PDAs, even with
an unplanned start to RRT, achieved a high level of concor-
dance between the chosen and final modality [20].
Unfortunately, the GADDPE initiatives have not
improved the percentage of patients starting dialysis via
emergency treatment; this has remained at 45.6%. How-
ever, although HD was still the starting option for most of
the educated unplanned patients, their final method after
recovering from the acute condition showed a more bal-
anced dialysis distribution that was closer to that of the
whole educated group [20].
In addition, informed consent has been made mandatory
in Madrid and Andalusia.
A recent study surveying patient satisfaction with the
educational process for RRT choice in 13 GADDPE-led
hospitals and one dialysis clinic found significant
improvement since the beginning of GADDPE’s activities
in 2009. For example, in 2009, a total of 32% of respon-
dents felt the explanation they received about the advan-
tages and disadvantages of HD was inadequate or very
inadequate and 77% felt the same way about the explana-
tion they received about PD [18]. After 6 years, these
figures were 9 and 1.7%, respectively, in units with leaders
who were members of GADDPE (GADDPE survey carried
out in 2015 and 2016 on CKD patient satisfaction with the
educational process for RRT choice; unpublished data.
Participant hospitals are listed in the ‘Acknowledgments’
section of this paper.). Overall, patients surveyed in 2015
and 2016 were very satisfied with the education process for
RRT choice, with an average score of 8.5 out of 10, and
differences between patients who opted for PD and those
who chose HD were minimal (unpublished data) (see
Table 1). This is in line with the previously mentioned
research showing that free choice, assisted by PDAs, leads
to an equal distribution of those choosing PD versus HD
[20].
6.2 Increasing Awareness Among Healthcare
Authorities
Given that Spain is a highly regionalized country, some
GADDPE members were appointed as regional
spokespersons. Since the very beginning, comprehensive
Table 1 Comparison of the worst-rated aspects of the educational process in the 2009 patients’ survey (national) and 2015–2016 survey
(GADDPE-led hospitals). Percentage of responses assessing each aspect as ‘‘inadequate or very inadequate’’
Dialysis option chosen by
respondents
2009 National survey
(%)
2015–2016 GADDPE survey
(%)
Teaching materials HD 60.2 14.7
DP 83.3 1.7
Explanation of advantages and
disadvantages
HD 32.3 8.8
DP 76.7 1.7
Information on all options HD 66.7 5.6
DP 70.0 1.7
Detailed information for each option HD 48.9 6.3
DP 75.8 1.7
Time dedicated by clinician HD 34.5 3.1
DP 66.7 3.2
Clarity of explanations HD 49.3 3.6
DP 63.3 3.5
Predisposition of the specialist to inform HD 38.0 4.1
DP 57.2 0.0
GADDPE acronym for Spanish Support Group for Peritoneal Dialysis Development, HD haemodialysis, PD peritoneal dialysis
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campaigns were undertaken to engage healthcare policy
makers from national and regional health authorities and
hospital managers across Spain, with more than 70 face-to-
face meetings. One of the most important tools used for
these discussions was the GADDPE White Paper, in which
both the main barriers to PD use and the proposals to
overcome them were discussed with the different authori-
ties. Additionally, GADDPE members contacted the main
political parties in most of the regions using the same
rationale. This has led to key achievements such as the
approval of proposals promoting equity in patient access to
PD (in Madrid, Galicia, Extremadura, Aragon, Canary
Islands, and Valencia), a motion from the Senate asking the
government to take the necessary steps to promote PD
usage for patients with renal insufficiency, the adoption of
CKD strategic plans (Balearic Islands, Madrid, Canary
Islands, and La Rioja), the inclusion of PD usage as quality
indicators in hospitals (Balearic Islands, Valencia, and
Castilla and Leon), plus a change in incentives to promote
PD in Valencia by including PD indicators in management
agreements of health professionals and hospital managers
[21].
However, the lack of adequate staffing in CKD and PD
units was identified as an important barrier to PD growth,
and although some regions have assigned additional
resources, the economic crisis has prevented PD units from
being adequately staffed across the whole country.
6.3 Improving Knowledge of Peritoneal Dialysis
Among Healthcare Professionals
Training programs for healthcare professionals about PD
and communication skills useful in discussing treatment
options with CKD patients have also been adopted as a
result of GADDPE efforts (Balearic Islands, Valencia,
Castilla and Leon Madrid, Aragon, Catalonia, and Canary
Islands). The development of an official PD training pro-
gram for nephrology fellows was an additional initiative
fostered by GADDPE and has been conducted four times
thus far.
Unfortunately, GADDPE has not yet been able to
increase the length of hands-on PD training for nephrology
trainees within hospitals. Nevertheless, the group continues
to lobby the National Council of Medical Specialities.
However, to raise awareness among health professionals,
they developed a number of information leaflets, the PD
White Paper and scientific articles were published, and
presentations were given by GADDPE members at national
and regional scientific and health economics-related con-
gresses. Two national workshops were organized that
brought together patients, healthcare authorities, and
healthcare professionals.
6.4 Expanding Communication Channels
Last but not least, 6 years of intense activity has resulted in
770 examples of media interaction (including major
national daily newspapers, national radio and TV, spe-
cialized publications, and digital channels, among others),
potentially reaching an audience of 64 million people [22]
(see Fig. 1 for distribution of media impacts by channel).
GADDPE has taken advantage of any single opportunity
to foster PD awareness through the media, including pub-
lishing articles, after every annual registry presentation,
patients’ testimonies, World Kidney Days, publishing
individual hospital outcomes, and so on.
The main claims disseminated by GADDPE to the
general population focus on the cost effectiveness of PD,
that PD offers greater autonomy and allows patients to
maintain working activities, the right of patients to choose
their treatments, and the results of implementing education
processes, amongst others.
All these initiatives have led to a steady increase in the
use of PD since 2009. As of 2015, the latest data available,
there were 858 more PD prevalent patients than in 2009,
representing a 38% increase. The absolute number of PD
incident patients increased by 47.5% in the same period
(see Figs. 2 and 3), with the national percentage of incident
patients on PD at 17% in 2015 [7]. In GADDPE-led units
surveyed in 2015–2016, those engaging in comprehensive
patient education have an incident PD proportion of 35%
(GADDPE, Survey on CKD patient satisfaction with the
educational process for RRT choice; carried out in 2015
and 2016; unpublished data. Participant hospitals are listed
in the ‘Acknowledgments’ section of this paper). This
suggests that bottom-up collaborative multi-stakeholder
initiatives such as GADDPE can have an important impact
on health policy, both from above (by advocating with
policy makers and achieving legislative changes) and from
below (by educating the choices of individual patients,
treating physicians, and provider units).
Fig. 1 Distribution of media impacts by channel 2009–2015
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A comparison with neighbouring countries during this
period provides perspective on the evolution of PD pene-
tration in Spain. Data from the ‘international comparisons’
in the 2016 US Renal Data System (USRDS) report [23]
indicate that Spain has the highest growth in the European
countries of PD prevalent dialysis patients (see Fig. 4).
7 The Most Important Learning Moments
The new element in this initiative was that the movement
started with patients and healthcare professionals rather
than policy makers, which is more usual and socially
expected.
The different stakeholders within GADDPE, adding
their efforts in a bottom-up initiative, created the momen-
tum to promote a shift towards increased informed patient
decision making about RRT choices and cost-effective
delivery of RRT.
8 GADDPE’s Future Perspectives
PD is not yet completely established in Spain, and although
the use of PD has been increasing since 2009, much of the
change involved the modification of processes and beha-
viours, requiring actions that would overcome inertia.
Therefore, GADDPE aims to continue working in the fol-
lowing areas:
• Disseminating knowledge about PD amongst healthcare
professionals, patients, authorities, and the general
population
• Improving training on PD for professionals
• Leveraging shared decision-making processes at
nephrology units to guarantee patients’ free choice
and implementing mandatory informed consent for
RRT choices
• Continuing to emphasize the positive effects of PD,
specifically that patients are able to carry on working
and thus reducing the risk of poverty and social
exclusion
• Increasing the awareness of healthcare professionals
and authorities to foster dialysis planning, favouring the
selection of more efficient treatment sequences by
considering patient care as a continuum.
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Finally, GADDPE’s aspiration is to continue focusing
the energy and enthusiasm of all its members to ensure
patients have access to shared decision making as well as
the long-term sustainability of RRT in Spain through PD
development.
9 Conclusions
The Spanish healthcare system, with its oversized HD
capacity and lack of dialysis planning, combined with a
lack of awareness of the benefits of PD among both
healthcare professionals and patients, required action to
correct an imbalance in RRT offerings that may negatively
affect patients’ health outcomes and healthcare costs.
Waiting for healthcare reform was unlikely to bring ben-
efits in the short to medium term, so a multi-stakeholder
group (GADDPE) was set up to initiate and sustain coor-
dinated efforts to act upon the barriers that led to this
unfavourable situation. Its activities targeted both policy
makers and individual patients and providers. After
5 years, the use of PD has increased significantly
throughout the country, and more so in hospitals whose
leaders are members of GADDPE. Patients in these units
are now more satisfied with the information they receive
than patients were before GADDPE’s activities began, and
a significant number of informed patients choose PD over
HD, leading to potentially important savings to the Spanish
social and healthcare systems. This shows that raising
awareness and gathering the right stakeholders to engage
decision makers can be a viable option to initiate profound
changes in healthcare provision.
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